PT  - JOURNAL ARTICLE
AU  - Williams, Alan L.
AU  - Newman, Raquelle S.
TI  - Heplisav-B vs Standard Hepatitis B Vaccine Booster for Health Care Workers
AID  - 10.1370/afm.240184
DP  - 2025 Mar 01
TA  - The Annals of Family Medicine
PG  - 162--164
VI  - 23
IP  - 2
4099  - http://www.annfammed.org/content/23/2/162.short
4100  - http://www.annfammed.org/content/23/2/162.full
SO  - Ann Fam Med2025 Mar 01; 23
AB  - Confidence in hepatitis B seroprotection for US health care workers includes a complete immunization series followed by a hepatitis B surface antigen antibody (anti-HBs) titer ≥10 mIU/mL. We compared standard hepatitis B vaccines to Heplisav-B (Dynavax Technologies Corp) as a single booster for young, healthy, previously vaccinated individuals. Participants (N = 242) had documentation of a single vaccination series and an anti-HBs titer <10 mIU/mL. In this cohort, 1 booster achieved seropositivity for 92.7% (95% CI, 84.8%-97.2%) of the standard hepatitis B vaccine group and 99.4% (95% CI, 96.6%-100.0%) of the Heplisav-B group. Both boosters are likely to produce seropositivity in this population.